10-Year Excess Mortality After First-Time Non–ST-Segment Elevation Myocardial Infarction: The Western Denmark Heart Registry | JACC: Advances | JACC: Advances

0:00I'm Darshan Brambad, podcast editor of the Jack Advances Team. In the April 2026 issue, the study 10 year excess mortality after first time non-ST segment elevation myocardial infarction. The Western Denmark Heart Registry is by first author Dr. Lawrence and senior author Dr. Maine from the Ahus University Hospital Denmark. In ST segment elevation myocardial infarction patients, recent evidence showed an almost similar 10 year mortality in 90-day survivors when compared with a matched general population. Whether this finding also applies to contemporary patients with non-ST segment elevation myocardial infarction or NSTEMI remains unclear. The objective of this study was to examine the excess mortality in first time NSTEMI patients treated with percutaneous coronary intervention compared with a matched general population during the landmark periods of 0 to 30 days, 31 to 90 days and 91 days to 10 years. First

1:02time NSTEMI patients treated with percutaneous coronary intervention were identified in the Western Denmark Heart Registry from 2010 to 2022. Mortality was compared with a general population cohort matched by age, sex and calendar year. The study included 10,748. First time NSTEMI patients treated with percutaneous coronary intervention and 53,739 matched individuals. The median follow-up was six years and NSTEMI patients had higher mortality in all landmark periods than the general population. 1.9% excess mortality from 0 to 30 days has a ratio of 8.90, 0.5% from 31 to 90 days has a ratio of 2.54 and a 6.1% excess mortality from 91 to 10 years has a ratio of 1.26. Notably, this excess risk was almost exclusively confined to patients with a higher

2:03comorbidity burden excess mortality 22%. In conclusion, among first time NSTEMI patients treated with percutaneous coronary intervention, 90 day survivors had a substantially higher 10 year excess mortality than the matched general population. This excess mortality was primarily driven by NSTEMI patients with high baseline comorbidity burden.